Combination Laser Platform Treats Glaucoma and Cataract

An integrated laser offers ophthalmologists a versatile armamentarium for treating both cataract and glaucoma in an efficient combination platform.

The Optimis Fusion integrated laser combines advanced selective laser trabeculoplasty (SLT) photoregeneration therapy and traditional yttrium aluminium garnet (YAG) photodisruption to provide a platform for managing glaucoma and lowering intraocular pressure. The SLT therapy works by targeting melanin-rich cells that absorb the laser energy to induce a healing response, improving the function of the trabecular meshwork. Laser energy is delivered in short, fixed pulses over a large, homogeneous spot size, resulting in no thermal damage to the trabecular meshwork, making it a repeatable procedure.

The YAG mode delivers high-performance photodisruption for capsulotomy and peripheral iridotomy surgical procedures. The gaussian laser beam profile allows for precise laser delivery at minimum energy levels, avoiding adverse side effects such as lens pitting. Precise tissue targeting is achieved with the advanced two-point aiming beam, allowing for fast and accurate targeting of the capsule, and an adjustable anterior and posterior offset feature for easy focus adjustment in front of, behind, or at the point of disruption. The Optimis Fusion integrated laser is a product of Quantel Medical (Clermont-Ferrand, France).

“We are extremely excited to bring our breakthrough laser platform to the US market,” said Jean-Marc Gendre, CEO of Quantel Medical. “The Optimis Fusion has proven to be a very attractive laser platform since introduction earlier this year in other markets. Driving the acceptance of this product introduction is the ability to combine a 532 nm monospot or multispot retina laser, a unique feature to Quantel's laser line.”

Related Links:
Quantel Medical